CN117653672A - Application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products - Google Patents
Application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products Download PDFInfo
- Publication number
- CN117653672A CN117653672A CN202311663929.8A CN202311663929A CN117653672A CN 117653672 A CN117653672 A CN 117653672A CN 202311663929 A CN202311663929 A CN 202311663929A CN 117653672 A CN117653672 A CN 117653672A
- Authority
- CN
- China
- Prior art keywords
- bal531
- digestion
- bifidobacterium animalis
- product
- animalis subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001134770 Bifidobacterium animalis Species 0.000 title claims abstract description 51
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims abstract description 51
- 230000029087 digestion Effects 0.000 title claims abstract description 33
- 230000001737 promoting effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 235000013365 dairy product Nutrition 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 201000010538 Lactose Intolerance Diseases 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 230000013777 protein digestion Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 abstract description 14
- 108010059881 Lactase Proteins 0.000 abstract description 14
- 108010005774 beta-Galactosidase Proteins 0.000 abstract description 14
- 229940116108 lactase Drugs 0.000 abstract description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 14
- 239000004382 Amylase Substances 0.000 abstract description 11
- 102000013142 Amylases Human genes 0.000 abstract description 11
- 108010065511 Amylases Proteins 0.000 abstract description 11
- 108010059892 Cellulase Proteins 0.000 abstract description 11
- 108091005804 Peptidases Proteins 0.000 abstract description 11
- 239000004365 Protease Substances 0.000 abstract description 11
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 11
- 235000019418 amylase Nutrition 0.000 abstract description 11
- 229940106157 cellulase Drugs 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 102000004882 Lipase Human genes 0.000 abstract description 9
- 108090001060 Lipase Proteins 0.000 abstract description 9
- 239000004367 Lipase Substances 0.000 abstract description 9
- 235000019421 lipase Nutrition 0.000 abstract description 9
- 235000013336 milk Nutrition 0.000 abstract description 9
- 239000008267 milk Substances 0.000 abstract description 9
- 210000004080 milk Anatomy 0.000 abstract description 9
- 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 abstract description 8
- 230000014509 gene expression Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 7
- 235000019156 vitamin B Nutrition 0.000 abstract description 7
- 239000011720 vitamin B Substances 0.000 abstract description 7
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 abstract description 6
- 108010078791 Carrier Proteins Proteins 0.000 abstract description 5
- 238000000354 decomposition reaction Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 20
- 239000000843 powder Substances 0.000 description 19
- 239000001963 growth medium Substances 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 16
- 230000004151 fermentation Effects 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 15
- 238000012258 culturing Methods 0.000 description 14
- 238000009630 liquid culture Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 239000002054 inoculum Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000021552 granulated sugar Nutrition 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000015263 low fat diet Nutrition 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 108010041102 azocasein Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000002975 protease activity determination Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the technical field of microorganisms, in particular to application of bifidobacterium animalis subspecies of milk BAL531 with a preservation number of CGMCC No.17329 in preparation of digestion promoting products. According to experimental study, the bifidobacterium animalis subspecies of the milk BAL531 has strong protease production capability, and can effectively promote digestion and decomposition of proteins in food; has strong lactase producing capability, can effectively promote the digestion and decomposition of lactose in food, and further alleviate or avoid lactose intolerance symptoms; has stronger lipase producing capability, and is beneficial to the digestion and absorption of fat; meanwhile, the method also has certain amylase and cellulase production capacity, B vitamin synthesis capacity and capacity of improving SERT gene expression of a 5-hydroxytryptamine transporter. Therefore, the method can be used for preparing digestion promoting products, and the obtained products are particularly suitable for people with large dairy product intake.
Description
Technical Field
The invention relates to the technical field of digestion promoting products, in particular to application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products.
Background
Healthy dietary structure is extremely important to the human body, while the function and absorption of nutrients in foods are key to their function. For example, high fiber foods can promote intestinal peristalsis, but for people with poor digestive functions, nutrients in the foods are not easy to absorb, and dyspepsia is aggravated; fat is critical to the operations of the heart, liver, lung, bones, immune system and the like, long-term low-fat diet can cause bile to accumulate in the gall bladder and slowly concentrate to become sticky, when more fat is suddenly supplemented, the bile is difficult to smoothly flow into the small intestine, the supplemented fat cannot be truly utilized, and the sticky bile can cause toxin accumulation to damage health; lactose is present in various dairy products, and when the secretion of lactase is insufficient, digestive system symptoms such as diarrhea, abdominal distension, abdominal pain and the like can appear when the dairy product is eaten or drunk.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the application of bifidobacterium animalis subspecies lactis BAL531 in preparing digestion promoting products, and the strain has strong protease and lactase producing capability and strong lipase producing capability, has certain amylase and cellulase producing capability and B vitamin synthesizing capability, can improve the SERT gene expression of a 5-hydroxytryptamine transporter, and can be used for preparing the digestion promoting products.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
the application of Bifidobacterium animalis subspecies of BAL531 with the preservation number of CGMCC No.17329 in preparing digestion promoting products. The strain is preserved in China general microbiological culture Collection center (China general microbiological culture Collection center) with a preservation address of Beijing, chaoyang area, north Chenxi Lu No.1, 3, and China academy of sciences microbiological study, at 2019, 03 and 13. The bifidobacterium animalis subspecies BAL531 strain has been disclosed in patent application number CN201910356855.0 entitled "a probiotic composition suitable for diabetic patients and uses thereof".
Experimental study shows that the bifidobacterium animalis subspecies of the BAL531 has strong protease production capability and can effectively promote digestion and decomposition of proteins in food; has strong lactase producing capability, can effectively promote the digestion and decomposition of lactose in food, and further alleviate or avoid lactose intolerance symptoms; has strong lipase producing ability, and is beneficial to the digestion and absorption of fat. The effect of the above makes the bifidobacterium animalis subspecies of BAL531 be used for preparing digestion promoting products, and is especially suitable for people with large milk product intake.
Meanwhile, the bifidobacterium animalis subspecies BAL531 also has certain amylase and cellulase production capacity, B vitamin synthesis capacity and 5-hydroxytryptamine transporter SERT gene expression improvement capacity, and can play roles in promoting starch and cellulose decomposition, supplementing B vitamins of organisms and promoting gastrointestinal peristalsis to a certain extent, so that the digestion promotion effect is enhanced.
Preferably, the product contains a live strain of said bifidobacterium animalis subspecies BAL531 or a metabolite thereof.
Preferably, the product is a product for promoting protein digestion.
Preferably, the product is a product for promoting lactose digestion and/or improving lactose intolerance.
Preferably, the product is a product for promoting fat digestion.
Preferably, the above products include medicines, health foods, foods and food additives, wherein the dosage forms of medicines, health foods include, but are not limited to, conventional dosage forms such as powders, tablets, granules or solutions, and the forms of foods include, but are not limited to, liquid drinks, solid drinks, cold cakes, soft sweets, dairy products and the like.
Preferably, the product is a dairy product. The dairy product often contains more protein, fat and lactose, and the bifidobacterium animalis subspecies of the BAL531 has stronger protease, lipase and lactase production capacity, so that the dairy product prepared from the bifidobacterium animalis subspecies of the BAL531 is easier to digest and absorb.
Preferably, the product is a dairy additive.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The function and absorption of nutrients in foods is critical to the functioning of a healthy diet. High fiber foods are not digestible for people with poor digestive function and can exacerbate dyspepsia; fat digestion may be affected by long-term low-fat diets; lactose intake can lead to lactose intolerance symptoms when lactase is deficient. The probiotics can regulate intestinal flora of human bodies so as to promote digestion, however, not all probiotics can play an ideal role, and the effects of directly improving the activity of digestive enzymes of organisms and promoting digestion are rarely reported.
The invention provides an application of bifidobacterium animalis subspecies of milk BAL531 with a preservation number of CGMCC No.17329 in preparing digestion promoting products based on a large amount of researches. The bifidobacterium animalis subspecies BAL531 has strong protease and lactase production capability, strong lipase production capability, certain amylase and cellulase production capability, B vitamins synthesis capability and capability of improving SERT gene expression of a 5-hydroxytryptamine transporter, and can be used for preparing digestion promoting products. The forms of the product include, but are not limited to, pharmaceuticals, health foods, and food additives. The dosage forms of the medicines and the health foods comprise conventional dosage forms such as powder, tablets, granules or solutions, and the forms of the foods comprise liquid drinks, solid drinks, cold cakes, soft sweets, dairy products and the like.
When the product is prepared, other auxiliary materials are added according to the requirement, and the product is prepared by a conventional method.
For example, in preparing a dairy product, it may be prepared as follows: sterilizing fresh cow milk, dissolving white granulated sugar into the cow milk, inoculating bifidobacterium animalis subspecies of milk BAL531, fermenting at 40-42 ℃ until the pH value is 4.4-4.5, refrigerating and after-ripening to obtain the fermented yogurt. Diluting the fermented yogurt with water solution containing correctant such as syrup, and flavoring to obtain fermented milk beverage.
In the preparation of soft sweets, the following method can be adopted: the soft candy is prepared by spraying mixture of animal bifidobacterium milk subspecies BAL531 and glazing agent on the surface of soft candy semi-finished product prepared from common raw materials of soft candy after molding and before drying. The surface of the soft candy can be further modified by other polishing agents.
In preparing the powder, the powder can be prepared as follows: mixing the animal bifidobacterium lactis BAL531 freeze-dried powder, prebiotics, fruit and vegetable powder, xylitol and other auxiliary materials, and packaging to obtain a powder product of the animal bifidobacterium lactis BAL531, wherein the end product can be prepared into product specifications according to different viable counts, for example, each independently packaged powder can contain 100-300 hundred million viable counts of the animal bifidobacterium lactis BAL 531. Wherein the prebiotic is selected from at least one of fructo-oligosaccharide, isomaltooligosaccharide, isomaltulose, chitosan oligosaccharide or mannooligosaccharide.
In preparing tablets, the following procedure may be used: mixing animal Bifidobacterium lactis BAL531 lyophilized powder, prebiotics and common tablet raw materials such as pregelatinized starch, microcrystalline cellulose, magnesium stearate, pulvis Talci, sweetener and essence, etc. according to conventional proportion, granulating, and mechanically tabletting. The pressure can be adjusted according to the hardness requirement of the product during tabletting. Wherein the prebiotic is selected from at least one of fructo-oligosaccharide, isomaltooligosaccharide, isomaltulose, chitosan oligosaccharide or mannooligosaccharide.
In preparing the granule, the preparation method comprises the following steps: mixing animal Bifidobacterium lactis BAL531 lyophilized powder, prebiotics, filler, sweetener, essence, etc., granulating by conventional method, preparing product according to gram weight or viable count, and packaging. The prebiotic is selected from at least one of fructo-oligosaccharide, isomaltooligosaccharide, isomaltulose, chitosan oligosaccharide or mannooligosaccharide; the filler may be at least one of microcrystalline cellulose or pregelatinized starch.
When the product is prepared, the adopted bifidobacterium animalis subspecies of the BAL531 freeze-dried powder can be prepared according to the following method:
inoculating the bifidobacterium animalis subspecies BAL531 frozen and preserved at the temperature of minus 80 ℃ to a fresh and improved MRS culture medium for anaerobic culture at the temperature of 37 ℃ for 24 hours, and harvesting first-stage seeds; transferring the first-level seeds to a fresh improved MRS culture medium in an inoculum size of 5%, carrying out anaerobic culture for 24 hours at 37 ℃, and harvesting second-level seeds; transferring the second-level seed liquid to a fresh improved MRS culture medium according to an inoculum size of 5%, performing anaerobic culture for 20-24 h at 37 ℃, centrifuging for 10min at 4000g at 4 ℃, discarding the supernatant, washing bacterial mud for 2 times by using sterile normal saline, uniformly mixing the bacterial mud with a protective agent according to a ratio of 1:2.5 (m/v), pre-freezing for 12h at-70 ℃, then placing in a freeze dryer for vacuum freeze-drying, and crushing to obtain the bifidobacterium animalis subspecies of milk BAL531 freeze-dried powder. Wherein the protective agent can be prepared by the following method: 10 to 15g of skim milk powder, 4 to 9g of trehalose, 3 to 7g of sucrose, 1 to 2g of glycerol, 1 to 2g of gelatin, 1 to 2g of sodium glutamate, 0.1 to 0.2g of L-cysteine and 0.3 to 0.4g of manganese sulfate are uniformly mixed, and distilled water is added to be added to 100g of the mixture to obtain the compound.
The formulation and formulation of the media used in the following examples were as follows:
improvement of MRS culture medium: 20g of glucose, 10g of peptone, 6.5g of beef powder, 5g of yeast extract powder, 5g of sodium acetate, 2g of diammonium hydrogen citrate and diammonium hydrogen phosphatePotassium 2g, mgSO 4 ·7H 2 O 0.58g，MnSO 4 ·H 2 O0.25 g, cysteine hydrochloride 0.5g, tween 80 1mL, distilled water 1000mL.
Protease fermentation broth: 5.0g of casein, 5.0g of yeast extract, 5.0g of glucose, 2.0g of disodium hydrogen phosphate, 1.0g of potassium chloride, 0.1g of magnesium sulfate, pH 7.0-7.2 and sterilizing at 121 ℃ for 21 minutes.
Amylase fermentation broth: 10.0g of peptone, 10.0g of soluble starch, 5.0g of beef extract, 5.0g of sodium chloride, pH 7.2 and sterilizing at 121 ℃ for 21 minutes.
Lipase fermentation broth: 10.0g of peptone, 40.0g of glucose, 10.0g of olive oil, 0.5g of magnesium sulfate heptahydrate, 1.0g of dipotassium hydrogen phosphate, pH 7.5 and sterilizing at 121 ℃ for 21 minutes.
Cellulase fermentation broth: 10.0g of yeast powder, 15.0g of sodium carboxymethyl cellulose, 6.0g of sodium chloride, 0.1g of magnesium sulfate heptahydrate, 0.5g of potassium dihydrogen phosphate, 0.1g of calcium chloride, 2.0g of dipotassium hydrogen phosphate, 2.0g of ammonium sulfate, pH 7.0-7.2 and sterilizing at 121 ℃ for 21 minutes.
Lactase fermentation broth: lactose 10.0g, yeast powder 10.0g, magnesium sulfate 0.2g, pH6.8, and autoclaved at 115℃for 15min.
Example 1
The present example provides results of an investigation of the protease producing ability of bifidobacterium animalis subspecies BAL 531.
(1) Activating the bifidobacterium animalis subspecies BAL531 strain in a modified MRS liquid culture medium, and culturing for 24 hours in a 37 ℃ incubator to activate for 3 generations.
(2) Protease activity determination: inoculating activated bifidobacterium animalis subspecies BAL531 strain in a protease fermentation liquid culture medium according to an inoculum size of 5%, culturing for 3d at 37 ℃, taking fermentation supernatant, and detecting protease activity in the supernatant by using a protease activity kit. The total protease activity was measured to be 0.43 azocasein units/h/mL.
Example 2
The present example provides results of an investigation of the lactase producing ability of bifidobacterium animalis subspecies BAL 531.
(1) Activating the bifidobacterium animalis subspecies BAL531 strain in a modified MRS liquid culture medium, and culturing for 24 hours in a 37 ℃ incubator to activate for 3 generations.
(2) Lactase production activity determination of each strain: inoculating activated bifidobacterium animalis subspecies BAL531 strain in a lactase fermentation liquid culture medium according to an inoculum size of 5%, culturing for 3d at 37 ℃, taking fermentation supernatant, and detecting lactase activity in the supernatant by using a lactase activity kit. The lactase activity was detected to be 648U/mL.
Example 3
The present example provides the results of an investigation of the ability of bifidobacterium animalis subspecies BAL531 to produce lipase.
(1) Activating the bifidobacterium animalis subspecies BAL531 strain in a modified MRS liquid culture medium, and culturing for 24 hours in a 37 ℃ incubator to activate for 3 generations.
(2) Measurement of lipase production activity: inoculating activated bifidobacterium animalis subspecies BAL531 strain in a lipase fermentation liquid culture medium according to an inoculum size of 5%, culturing for 3d at 37 ℃, taking fermentation supernatant, and detecting lipase activity in the supernatant by using a lipase activity kit. The lipase activity was detected to be 15.5nmol/min/mL.
Example 4
The present example provides results of an investigation of the amylase producing ability of bifidobacterium animalis subspecies BAL 531.
(1) Activating the bifidobacterium animalis subspecies BAL531 strain in a modified MRS liquid culture medium, and culturing for 24 hours in a 37 ℃ incubator to activate for 3 generations.
(2) Determination of amylase activity: inoculating activated bifidobacterium animalis subspecies BAL531 strain in an amylase fermentation liquid culture medium according to an inoculum size of 5%, culturing for 3d at 37 ℃, taking fermentation supernatant, and detecting amylase activity in the supernatant by using an amylase activity kit. The amylase activity was measured to be 0.60mg/min/mL.
Example 5
The present example provides results of an investigation of the cellulase-producing ability of bifidobacterium animalis subspecies BAL 531.
(1) Activating the bifidobacterium animalis subspecies BAL531 strain in a modified MRS liquid culture medium, and culturing for 24 hours in a 37 ℃ incubator to activate for 3 generations.
(2) And (3) measuring cellulase production activity: inoculating activated bifidobacterium animalis subspecies BAL531 strain into a cellulase fermentation liquid culture medium according to an inoculum size of 5%, culturing for 3d at 37 ℃, taking fermentation supernatant, and detecting cellulase activity in the supernatant by using a cellulase activity kit. The cellulase activity was detected to be 35. Mu.g/h/mL.
Example 6
The present example provides results of an investigation of the ability of bifidobacterium animalis subspecies milk bel 531 to synthesize vitamin B.
(1) Activating the bifidobacterium animalis subspecies BAL531 strain in a modified MRS liquid culture medium, and culturing for 24 hours in a 37 ℃ incubator to activate for 3 generations.
(2) Inoculating activated bifidobacterium animalis subspecies BAL531 strain in an MRS liquid culture medium according to an inoculum size of 5%, culturing for 3d at 37 ℃, taking fermentation supernatant, and detecting the vitamin B group content in the supernatant by using a vitamin B1, B2, B6 and B12 content detection kit. Through detection, the concentration of Vb1 in the supernatant is 1.0 mug/mL, the concentration of Vb2 is 15 mug/mL, the concentration of Vb6 is 0.55 mug/mL, and the concentration of Vb12 is 0.64 mug/mL.
Example 7
The present example provides the results of an investigation of bifidobacterium animalis subspecies BAL531 to increase the expression of the 5-hydroxytryptamine transporter SERT gene.
(1) Activating Bifidobacterium animalis subspecies BAL531 strain in improved MRS liquid culture medium, culturing in 37 deg.C incubator for 24 hr, activating for 3 generations, and adjusting strain concentration to 10 8 CFU/mL。
(2) After resuscitating HT-29 cells, the cells are recovered in 5% CO 2 Culturing at 37deg.C in incubator, collecting 3 rd generation HT-29 cells, adjusting cell concentration, and adjusting density to 2.5X10 5 Inoculating 2mL of each cell/mL into 24-well plate, and inoculating 5% CO at 37deg.C 2 Incubate in incubator for 24h. After cell attachment, the supernatant was discarded, 2mL of MyCoy's 5A medium (10% serum) was added to each well, 200. Mu.L of the concentration-adjusted bacterial suspension was added, 200. Mu.L of MyCoy's 5A medium (10% serum) was added to the control,3 replicates of each group at 37℃with 5% CO 2 Incubating for 24h under the condition, and collecting cells of each well.
(3) RNA level verification
Cell RNA extraction: RNA Easy Fast animal tissue/cell total RNA extraction kit (centrifugation column) DP451 was used and then the RNA integrity, purity and concentration was measured.
Reverse transcription: the FastKing cDNA first Strand Synthesis kit (ungrouped) catalog number was used: KR116 synthesizes cDNA, and needs to be stored at low temperature.
Fluorescent quantitative PCR detects 5-hydroxytryptamine transporter (SERT) gene expression.
Primer design: the housekeeping gene used was 18SrRNA. The sequences of the primers are shown in Table 1.
TABLE 1 primer sequences
| Primer name | Primer sequence (5 '-3') |
| SERT-F | AATGGGTACTCAGCAGTTCC |
| SERT-R | CCACAGCATAGCCAATCAC |
| 18SrRNA-F | TGTGATGCCCTTAGATGTCC |
| 18SrRNA-R | GATAGTCAAGTTCGACCGTC |
Program setting: 95 ℃ for 15min;40 cycles: 95℃for 10s,60℃for 30s and 72℃for 30s; melting curve: the temperature is 65-95 ℃ and the temperature is kept at 0.5 ℃ in each step for 5s.
Experimental results show that the bifidobacterium animalis subspecies BAL531 has a certain capacity of improving the SERT gene expression of a 5-hydroxytryptamine transporter, and the SERT mRNA gene expression multiple is 1.5 times, so that the bifidobacterium animalis subspecies BAL531 has the capacities of improving gastrointestinal motility and accelerating gastric emptying, thereby promoting food digestion.
Example 8
The present example provides the use of bifidobacterium animalis subspecies milk bel 531 for the preparation of a digestion promoting food.
1. Fermented yogurt for promoting digestion
Sterilizing fresh cow milk, adding 5% white granulated sugar, stirring to dissolve completely, inoculating 0.05% bifidobacterium animalis subspecies BAL531 at 40-42 ℃, fermenting at 40-42 ℃ to pH 4.4-4.5, refrigerating and aging to obtain the fermented yogurt.
2. Digestion-promoting fermented milk beverage
Sterilizing fresh cow milk, adding 5% white granulated sugar, stirring to dissolve completely, inoculating 0.05% bifidobacterium animalis subspecies BAL531 at 40-42 ℃, fermenting at 40-42 ℃ to pH 4.4-4.5, refrigerating and aging to obtain the fermented yogurt. Preparing syrup from drinking water and fructose-glucose syrup, sterilizing at 95deg.C for 5min, cooling to 42deg.C, mixing with fermented yogurt, adding correctant and essence according to taste requirement, homogenizing, packaging, and refrigerating to obtain fermented milk beverage.
Example 9
The embodiment provides application of bifidobacterium animalis subspecies lactis BAL531 in preparing health-care food for promoting digestion.
1. Digestion promoting powder
And (3) mixing 48% of bifidobacterium animalis subspecies BAL531 freeze-dried powder, 27% of fructo-oligosaccharides and 25% of xylitol according to mass percentage, preparing product specifications according to the number of viable bacteria, and packaging to obtain the powder containing bifidobacterium animalis subspecies BAL 531.
2. Digestion promoting tablet
According to the mass percentage, 32 percent of animal bifidobacterium lactobacillus subspecies BAL531 freeze-dried powder, 7 percent of isomaltooligosaccharide, 28 percent of microcrystalline cellulose, 31 percent of pregelatinized starch, 0.4 percent of magnesium stearate, 0.6 percent of talcum powder, 0.5 percent of sweetener and 0.5 percent of essence are taken, uniformly mixed, the product specification is prepared according to gram weight or viable count, and the mixture is mechanically pressed into tablets by a tablet press. The pressure can be adjusted according to the hardness requirement of the product during tabletting.
3. Digestion-promoting granule
Taking the bifidobacterium animalis subspecies of BAL531 freeze-dried powder, isomaltooligosaccharide, pregelatinized starch and powdered sugar according to the mass ratio of 8:2:3:2, uniformly mixing, granulating by a wet method, drying at a low temperature, adding 0.6% talcum powder and 0.5% essence, preparing product specifications according to gram weight or viable count, and sub-packaging to obtain the granules.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, or alternatives falling within the spirit and principles of the invention.
Claims (8)
1. The application of Bifidobacterium animalis subspecies of BAL531 with the preservation number of CGMCC No.17329 in preparing digestion promoting products.
2. Use according to claim 1, characterized in that said product contains a live strain of said bifidobacterium animalis subspecies BAL531 or a metabolite thereof.
3. The use according to claim 2, wherein the product is a product for promoting protein digestion.
4. Use according to claim 2, wherein the product is a product for promoting lactose digestion and/or improving lactose intolerance.
5. Use according to claim 2, wherein the product is a product for promoting fat digestion.
6. The use according to any one of claims 1 to 5, wherein the product comprises a pharmaceutical product, a health food, a food and a food additive.
7. The use according to claim 6, wherein the product is a dairy product.
8. The use according to claim 6, wherein the product is a dairy additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311663929.8A CN117653672A (en) | 2023-12-06 | 2023-12-06 | Application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311663929.8A CN117653672A (en) | 2023-12-06 | 2023-12-06 | Application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117653672A true CN117653672A (en) | 2024-03-08 |
Family
ID=90065685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311663929.8A Pending CN117653672A (en) | 2023-12-06 | 2023-12-06 | Application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117653672A (en) |
-
2023
- 2023-12-06 CN CN202311663929.8A patent/CN117653672A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396046B (en) | Probiotics yoghourt and manufacture method and use thereof | |
| CN103004984B (en) | Lactobacillus plantarum fermented milk and preparation method thereof | |
| CN109929779B (en) | Probiotic preparation containing bioactive peptide and preparation method and application thereof | |
| US8551543B2 (en) | Symbiotic maple product compositions and methods | |
| CN108782758B (en) | Fermented synbiotic goat milk powder and preparation method thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| EP1513541B1 (en) | Method for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract | |
| CN108913639A (en) | A kind of Lactobacillus rhamnosus complexing agent and its preparation method and application | |
| TWI739495B (en) | Composition for promoting defecation and use therefor | |
| CN109287749B (en) | Double-protein fermented milk rich in active lactobacillus plantarum and preparation method thereof | |
| CN105918460A (en) | Probiotics cereal yogurt and preparation method thereof | |
| CN107868769A (en) | A kind of high activity bifidobacteria freeze-dried vaccine powder producing method and application | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| CN105661230A (en) | Probiotic functional beverage and probiotic food prepared from Lens culinaris by fermentation | |
| CN112616925A (en) | Double-protein fermented milk and preparation method thereof | |
| CN105594854A (en) | Yogurt fermentation bacterial agent, full-bacterial yogurt and preparation method of full-bacterial yogurt | |
| CN108902314B (en) | Double-protein fermented milk beverage rich in active lactobacillus plantarum and preparation method thereof | |
| CN105724571B (en) | Isotonic probiotics preparation and preparation method thereof | |
| CN117653672A (en) | Application of bifidobacterium animalis subspecies lactis BAL531 in preparation of digestion promoting products | |
| US20220193155A1 (en) | Microbial compositions and methods for greater tolerability and prolonged shelf life | |
| CN117530965A (en) | Application of lactobacillus plantarum LP45 in preparation of gastrointestinal motility improving product | |
| CN113908177A (en) | BF839, bifidobacterium and facultative probiotic culture solution and preparation thereof | |
| CN117660246A (en) | Lactococcus lactis subspecies S28 for high-yield metabolic enzyme and application thereof | |
| CN117653671A (en) | Application of bifidobacterium bifidum B11 in preparation of products for improving functional dyspepsia | |
| CN110897166A (en) | Edible composition containing probiotics and casein phosphopeptides and having digestion promoting effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |